Predictmedix Receives Purchase
Order Valued at $500k from MGM Healthcare for AI-Powered Safe Entry
Stations to Enhance Healthcare Operations
Toronto, Ontario - March 30, 2023
-- InvestorsHub NewsWire -- Predictmedix Inc. ("Predictmedix" or
the "Company") (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP), a leading provider of rapid
health screening solutions powered by proprietary artificial
intelligence (AI), today announced a purchase order from one of the
largest Government hospital groups in India, MGM Healthcare, for
the company's AI-powered Safe Entry Stations. The purchase order
was followed by the recently completed third-party, 400-patient
clinical study conducted by MGM Healthcare in which the
scope
was to determine the effectiveness of Predictmedix's AI-powered
screening technology.
Safe Entry is a comprehensive and
global risk management solution that utilizes a fully patented
system to rapidly and autonomously screen for individuals' key
vitals. The Safe Entry Station is a walk-thru system where an
individual stands in front of the unit for 2-3 seconds while
multi-spectral imaging cameras gather the necessary information to
determine the physiological state of an individual. Parameters like
temperature, heart rate, and respiration rate are collected
non-invasively and the AI/ML algorithms compute a result. Vitals
hold key insight into an individual's state, whether they're
dealing with health complications, influenza, fatigue or even
impairment. Safe Entry does not capture or store personal identity
information, ever.
MGM Healthcare is a prominent
group of medical universities in India, comprising multiple
hospitals across the country. Known for their state-of-the-art
facilities and commitment to delivering exceptional healthcare
services, MGM Healthcare has chosen to deploy five Safe Entry
Stations to screen patients for infectious diseases and triage
purposes. This purchase order represents a substantial investment,
with a value of approximately $500,000 CAD spread over a three-year
period. By choosing to implement Predictmedix's AI-powered
screening technology, MGM Healthcare is demonstrating its
commitment to providing innovative solutions that improve patient
outcomes and enhance the efficiency of healthcare
operations.
Aside from providing a quick and
effective method of screening for impairment and infectious
diseases, Safe Entry's AI-powered technology also helps healthcare
facilities overcome staffing challenges. With limited resources,
hospitals need to ensure that their staff is being utilized in the
most efficient way possible. By quickly analyzing an individual's
vital signs, Safe Entry can reduce wait times and processing times
for patients, enabling healthcare providers to focus on providing
timely care to patients who need it most. This non-invasive method
of collecting vitals is more comfortable for patients, which can
lead to a better overall patient experience. By improving patient
care and streamlining operations, Safe Entry offers a comprehensive
solution for healthcare facilities looking to enhance their
capabilities.
"With over 69,000 hospitals in
India alone, having our footing in the healthcare space is a major
achievement for Predictmedix. This positions us to unlock immense
opportunities for expanding our cutting-edge healthcare technology
in South Asia and ASEAN countries. South Asia and ASEAN countries
present a substantial opportunity for Predictmedix to enhance
healthcare in regions with large populations. Furthermore, our
technology has shown promising results with the recently completed
1600-person clinical study at an Indonesian University.
We strongly believe our innovative
tech can play a crucial role in improving healthcare outcomes and
easing the burden on healthcare systems, and we look forward to
expanding our presence in these regions," stated Dr. Rahul Kushwah,
COO at Predictmedix."
"Securing a purchase order
directly from MGM Healthcare is a major achievement for
Predictmedix, as it validates the effectiveness and potential of
our technology in the healthcare sector. Our team has been
dedicated to commercializing this technology for some time, and the
fact that MGM Healthcare has conducted third-party clinical studies
with Safe Entry further underscores the confidence in our product.
We are excited to continue partnering with MGM Healthcare to
provide state-of-the-art healthcare solutions to patients across
India," commented Guru Bakshish Singh Sehgal, Head of Indian
Operations at Predictmedix.
About
Predictmedix Inc.
Predictmedix (CSE: PMED) (OTCQB:
PMEDF) (FRA:3QP) is an emerging provider of rapid health screening
and remote patient care solutions globally. The Company's Safe
Entry Stations - powered by a proprietary artificial intelligence
(AI) - use multispectral cameras to analyze physiological data
patterns and predict a variety of health issues including
infectious diseases such as COVID-19, impairment by drugs or
alcohol, fatigue or various mental illnesses. Predictmedix's
proprietary remote patient care platform empowers medical
professionals with a suite of AI-powered tools to improve patient
health outcomes. To learn more, please visit our website at
www.Predictmedix.com or follow us on Twitter, Instagram or
LinkedIn.
Public Relations
Contact
For further media information or
to set up an interview, please contact:
Nelson Hudes
Hudes Communications
International
(905) 660 9155
Nelson@hudescommunications.com
Dr. Rahul Kushwah
(647) 889 6916
Caution Regarding Forward-Looking
Information:
This news release may contain
forward-looking statements and information based on current
expectations. These statements should not be read as guarantees of
future performance or results of the Company. Such statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be
materially different from those implied by such statements.
Although such statements are based on management's reasonable
assumptions, there can be no assurance that such assumptions will
prove to be correct. We assume no responsibility to update or
revise them to reflect new events or circumstances. The Company's
securities have not been registered under the U.S. Securities Act
of 1933, as amended (the "U.S. Securities Act"), or applicable
state securities laws, and may not be offered or sold to, or for
the account or benefit of, persons in the United States or "U.S.
Persons", as such term is defined in Regulations under the U.S.
Securities Act, absent registration or an applicable exemption from
such registration requirements. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of the securities in the United States
or any jurisdiction in which such offer, solicitation or sale would
be unlawful. Additionally, there are known and unknown risk factors
which could cause the Company's actual results, performance or
achievements to be materially different from any Page 4 of 4 future
results, performance or achievements expressed or implied by the
forward-looking information contained herein, such as, but not
limited to dependence on obtaining regulatory approvals; the
ability to obtain intellectual property rights related to its
technology; limited operating history; general business, economic,
competitive, political, regulatory and social uncertainties, and in
particular, uncertainties related to COVID-19; risks related to
factors beyond the control of the Company, including risks related
to COVID-19; risks related to the Company's shares, including price
volatility due to events that may or may not be within such party's
control; reliance on management; and the emergency of additional
competitors in the industry.
All forward-looking information
herein is qualified in its entirety by this cautionary statement,
and the Company disclaims any obligation to revise or update any
such forward-looking information or to publicly announce the result
of any revisions to any of the forward-looking information
contained herein to reflect future results, events or developments,
except required by law.
Disclaimer: "The Company is not
making any express or implied claims that its product has the
ability to diagnose, eliminate, cure or contain the COVID-19 (or
SARS-2 Coronavirus) at this time."
THE CANADIAN SECURITIES EXCHANGE
HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF
THIS RELEASE.